Barbara Helen Hosein

Title: Innovations by Barbara Helen Hosein in Hepatitis C Detection

Introduction

Barbara Helen Hosein is an esteemed inventor based in New York, NY, who has made significant contributions to the field of medical diagnostics. With a total of four patents to her name, her work primarily focuses on the development of synthetic peptides that are crucial for the detection of antibodies related to hepatitis C virus (HCV) and other related viruses.

Latest Patents

Hosein's latest innovations include two notable patents. The first patent describes synthetic peptides that are specifically designed for the detection of antibodies to HCV. This groundbreaking invention presents a method for detecting the presence of HCV or NANBHV antibodies in body fluids by utilizing these unique peptides as antigens. The peptides are selected from both the envelope and non-structural protein regions, allowing for a more accurate diagnosis. The methods specified in this patent include enzyme-linked immunosorbent assay and other immunoassay procedures, and the peptides can also serve as immunogens in generating high titer antibodies to HCV or in vaccine development.

The second patent introduced by Hosein pertains to novel linear and branched peptides that are specific for diagnosing and preventing HCV infection. This invention is directed towards developing effective peptides containing at least one antigenic site useful in detecting HCV-associated antibodies using immunoassay techniques. Notably, this patent features preferred mixtures for detection and a new spliced peptide that can block non-specific reactivity associated with certain NS-3 conformational epitopes.

Career Highlights

Barbara Helen Hosein currently works at United Biomedical, Inc., where she continues to innovate in the realm of medical biotechnology. Her research has greatly enhanced the understanding and detection of hepatitis C, contributing to improved diagnostic methodologies and potential vaccine developments.

Collaborations

Throughout her career, Hosein has collaborated with several notable peers, including Chang Yi Wang and Chang-Yi Wang. These collaborations have facilitated a dynamic exchange of ideas and advancements in the field of peptide synthesis and virology.

Conclusion

In conclusion, Barbara Helen Hosein's inventive contributions in the detection of hepatitis C virus highlight her status as a leading figure in medical diagnostics. With her ongoing efforts at United Biomedical, Inc., and her innovative patents, she continues to impact the field positively, paving the way for advancements that could improve health outcomes for patients worldwide.